In addition, patients with HCC who have higher p-STAT3 levels exhibited poor clinical outcomes, and the median survival time of the high p-STAT3 group versus and low p-STAT3 groups were 28 and 45 months, respectively (Fig. S9E). This evidence concerns the gene STAT3 and hepatocellular carcinoma.